Compare ATEN & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEN | WVE |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2014 | 2015 |
| Metric | ATEN | WVE |
|---|---|---|
| Price | $18.19 | $16.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $21.50 | ★ $27.53 |
| AVG Volume (30 Days) | 684.1K | ★ 12.9M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | ★ 4.68 | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $284,406,000.00 | $109,230,000.00 |
| Revenue This Year | $12.37 | N/A |
| Revenue Next Year | $8.10 | $31.09 |
| P/E Ratio | $26.31 | ★ N/A |
| Revenue Growth | 10.27 | ★ 103.75 |
| 52 Week Low | $13.81 | $5.28 |
| 52 Week High | $21.90 | $21.73 |
| Indicator | ATEN | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 61.28 | 65.75 |
| Support Level | $17.76 | $6.93 |
| Resistance Level | $18.65 | $21.73 |
| Average True Range (ATR) | 0.33 | 1.51 |
| MACD | 0.16 | 1.14 |
| Stochastic Oscillator | 77.47 | 61.45 |
A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.